Progress toward a Malaria Vaccine

The broader scope of the Special Issue on “Progress towards a Malaria Vaccine” is to collate all the scientific efforts made towards the malaria vaccine development. Research articles, reviews, commentaries, short scientific reports, and mini-reviews covering various areas of malaria vaccine development including parasitology, immunology, vaccine development, vaccine efficacy and safety studies, clinical trials, animal models, molecular biology and vaccine targets, mathematical models, structural biology, and related topics could be part of the scope of this Special Issue.

Dear Colleagues,

Last year, the World Health organization (WHO) recommended RTS,S/AS01, a Plasmodium falciparum Circumsporozoite protein (CSP)-based pre-erythrocytic vaccine for children living at high-risk regions such as sub-Saharan Africa and other regions with high P. falciparum transmission. The vaccine has delivered a favorable safety profile and has shown significant reduction (30%) in malaria-prone areas. This has inspired several researchers around the world to develop advanced strategies and more efficient vaccines by identifying potential vaccine targets, different vaccine models (DNA, mRNA, Whole sporozoite, other subunit vaccines such as R21), immunization routes, different adjuvants, various vaccine carriers, etc., to achieve the WHO’s target of eliminating malaria by 2030. The significance of this Special Issue is to set a common platform for researchers working in advanced malaria vaccine development areas as mentioned in the scope of the Special Issue. We aim to cover most topics related to vaccine development, new targets, different vaccines, animal models, vaccine efficacy and safety profiles, and so on and so forth.

We are pleased to invite you (…)

• To submit your scientific work related to malaria vaccine development including experimental data, expert reviews, clinical study safety profile and efficacy, and commentary on the malaria vaccine development and advancements. This would be part of the Vaccines journal and should fit the scope of the journal.

This Special Issue aims to (…)

• Collate original scientific research articles, reviews, commentaries, short reports, and mini-reviews

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

• Different vaccines (mRNA, DNA, Subunit, whole parasite, etc.);
• Various adjuvants and route of vaccinations;
• Vaccine immunology;
• Targeted vaccine delivery;
• Statistical and Mathematical models in vaccine development;
• Clinical trials;
• Vaccine dose and immunization regimens;
• Structural biology;
• Vaccine efficacy;
• Vaccine safety profiles;
• Animal models;
• Novel vaccine targets. 

I/We look forward to receiving your contributions. 

Dr. Ganesh Ram Visweswaran
Dr. Kamalakannan Vijayan
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• various adjuvants and route of vaccinations
• vaccine immunology
• targeted vaccine delivery
• statistical and mathematical models in vaccine development
• clinical trials
• vaccine dose and immunization regimens
• structural biology
• vaccine efficacy
• vaccine safety profiles
• animal models
• novel vaccine targets